| Q33439263 | A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting |
| Q81765414 | Aberrant prothymosin-alpha expression in human bladder cancer |
| Q36774380 | Androgen receptor decreases the cytotoxic effects of chemotherapeutic drugs in upper urinary tract urothelial carcinoma cells |
| Q55190089 | Are all metachronous multifocal urothelial carcinoma created equal? |
| Q35205137 | Are urothelial carcinomas of the upper urinary tract a distinct entity from urothelial carcinomas of the urinary bladder? Behavior of urothelial carcinoma after radical surgery with respect to anatomical location: a case control study |
| Q89843696 | Arsenic exposure is associated with significant upper tract urothelial carcinoma health care needs and elevated mortality rates |
| Q34501651 | B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma |
| Q40738932 | BCAT1 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder |
| Q36108115 | Bladder cancer: a simple model becomes complex |
| Q37599160 | Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance |
| Q35682594 | CDCA5 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder |
| Q35989342 | CSF2 Overexpression Is Associated with STAT5 Phosphorylation and Poor Prognosis in Patients with Urothelial Carcinoma |
| Q36361826 | Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients |
| Q97565855 | Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma |
| Q33772260 | Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder |
| Q94464748 | Comparisons of prognosis between urothelial carcinoma of the upper urinary tract and bladder with pT3-4 cancer |
| Q37133629 | Complement Component 1, s Subcomponent Overexpression is an Independent Poor Prognostic Indicator in Patients with Urothelial Carcinomas of the Upper Urinary Tract and Urinary Bladder |
| Q35017773 | Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylation |
| Q60922825 | Deduction of Novel Genes Potentially Involved in Upper Tract Urothelial Carcinoma Using Next-Generation Sequencing and Bioinformatics Approaches |
| Q33982159 | Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis |
| Q38044251 | Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours |
| Q37514045 | Downregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder |
| Q60302268 | Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma |
| Q36294818 | Endoscopic Treatment of Upper Tract Urothelial Carcinoma |
| Q39860786 | Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. |
| Q41728557 | Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. |
| Q34788904 | FXYD3: A Promising Biomarker for Urothelial Carcinoma |
| Q34971588 | Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population |
| Q41153833 | GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder |
| Q45221749 | Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours |
| Q36362571 | Genomic Characterization of Upper Tract Urothelial Carcinoma |
| Q37962571 | Global epigenetic profiling in bladder cancer. |
| Q40986079 | HAS3 underexpression as an indicator of poor prognosis in patients with urothelial carcinoma of the upper urinary tract and urinary bladder |
| Q37199283 | HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma. |
| Q38176467 | Highlights from the first symposium on upper tract urothelial carcinoma |
| Q34520094 | HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma |
| Q33802832 | Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters |
| Q39173839 | IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder |
| Q54689960 | Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. |
| Q34333522 | Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker |
| Q86687959 | Independent prognostic factors for initial intravesical recurrence after laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma |
| Q86101321 | Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma |
| Q49874623 | Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. |
| Q81521507 | Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma |
| Q34659189 | Management of patients with upper urinary tract transitional cell carcinoma. |
| Q31166732 | Metastasis-associated in colon cancer 1 is a novel survival-related biomarker for human patients with renal pelvis carcinoma |
| Q51829109 | Micro-brushing-based technique to gain fresh urothelial cells for gene expression analysis. |
| Q47143259 | Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract |
| Q37982453 | Molecular mechanisms of cisplatin resistance in bladder cancer. |
| Q84146971 | Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma |
| Q41826957 | NFATc1 Expression as a Prognosticator in Urothelial Carcinoma of the Upper Urinary Tract. |
| Q36563911 | Necdin Overexpression Predicts Poor Prognosis in Patients with Urothelial Carcinomas of the Upper Urinary Tract and Urinary Bladder |
| Q34620160 | New facial papules in a 66-year-old woman with bladder cancer |
| Q45285322 | Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. |
| Q37373576 | Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration |
| Q38001253 | Perioperative chemotherapy for upper tract urothelial cancer |
| Q53334318 | Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma. |
| Q38180522 | Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis |
| Q28076374 | Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature |
| Q36833743 | Preoperative hydronephrosis and diabetes mellitus predict poor prognosis in upper urinary tract urothelial carcinoma |
| Q45349485 | Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma |
| Q33829648 | Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy |
| Q55667642 | Pro- and antiapoptotic markers in upper tract urothelial carcinoma associated with Balkan endemic nephropathy. |
| Q37133687 | Prognostic Impact of Thrombospodin-2 (THBS2) Overexpression on Patients with Urothelial Carcinomas of Upper Urinary Tracts and Bladders |
| Q38814000 | Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review |
| Q36924759 | Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma |
| Q33829643 | Prognostic value of preoperative plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) in patients with localized upper tract urothelial carcinoma |
| Q35216877 | Risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis |
| Q41620827 | Subcellular localisation of anillin is associated with different survival outcomes in upper urinary tract urothelial carcinoma. |
| Q64104130 | The evaluation of monocyte lymphocyte ratio as a preoperative predictor in urothelial malignancies: a pooled analysis based on comparative studies |
| Q39304455 | The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells |
| Q85962074 | The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study |
| Q37795337 | The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). |
| Q37071515 | The role of chemotherapy in upper tract urothelial carcinoma |
| Q53264010 | Urothelial carcinomas of the upper urinary tract are now recognised as a true and distinct entity from bladder cancer and belong fully to the broad spectrum of onco-urologic neoplasms. |
| Q47592266 | Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma. |